FDA WARNING_LETTER - Warrior Labz SARMS - June 20, 2023

The FDA issued a Warning Letter to Warrior Labz SARMS on June 12, 2023, following a May 2023 review of their website (https://warriorlabzsarms.com/) and Instagram (https://www.instagram.com/warrior_labz_sarms/). The letter identifies that Warrior Labz SARMS sells unapproved new drugs, including SARMs like “RAD-140 Testolone,” “MK-677 Ibutamoren,” “MK-2866 Ostarine,” and “LGD-4033 Ligandrol,” as well as “19-Nor Andro,” “4-Andro,” “BPC-157,” “TB-500,” “Viagra-Max Sildenafil,” and “Cialis-Max Tadalafil.”

Despite disclaimers like "research purpose only" and "not for human consumption," the FDA found evidence on the firm's websites establishing the products' intended use as drugs for human consumption, citing claims related to muscle growth, fat reduction, disease treatment, and sexual performance. The FDA has safety concerns regarding SARMs, noting risks of liver toxicity, heart attack, and stroke. Additionally, injectable and intranasal routes of administration for some products pose serious risks, including septicemia, sepsis, and local nasal damage.

These products are deemed "new drugs" under section 201